RxDoctor Payments Data

Linda Kessinger, MD

Family Medicine · Eleanor, WVNPI 1487634275

Payments from drug & device makers

$2,905in general payments, 2019–2025

Across 186 payments — averaging $15.62 each. Meals, travel, consulting and speaking fees, gifts and royalties reported by drug and device makers.

  • AbbVie$1K
  • Novo Nordisk$294
  • GSK$151
  • Pfizer$124
  • Biogen$120
  • Sage Therapeutics, LLC$118
  • plus $1K from 25 others

What the payments were for

  • Food & beverage$2,905100%

Most of this is food and beverage — typically meals provided during product presentations at a clinic or hospital. Nationally that is the single largest category of reported payments by count.

General payments by program year

19
20
21
22
23
24
25

Who reported the general payments

Companies are grouped under their corporate parent — a single manufacturer often files under several CMS reporting entities. Research and ownership payments are counted separately and are not in this table.

What the payments were tied to

Products named in the reported payments. Only payments of $100 or more are attributed here — the typical reported payment nationally is a meal worth about $16, and listing those product-by-product would be noise.

How this compares

$2,905 in reported general payments places this provider in the 80th percentile of 843 family medicine providers in West Virginia.

See all family medicine providers in West Virginia

Medicare billing

Part B allowed, 2024
$1,607
Medicare patients
48
Services billed
96

What this is not: this is the amount Original Medicare Part B allowed for services this provider billed in 2024. It is not their income. It excludes Medicare Advantage — now more than half of all Medicare enrollment — along with Medicaid and all commercial insurance, and it is gross practice revenue before staff, rent, supplies and malpractice premiums. CMS also suppresses any figure covering ten or fewer patients, so low-volume providers appear smaller than they are.

Most prescribed under Part D

DrugClaimsCost to plans & patients
OzempicSemaglutide103$132,899
Trelegy ElliptaFluticasone/Umeclidin/Vilanter84$71,975
EliquisApixaban79$63,845
JardianceEmpagliflozin53$54,072
TrulicityDulaglutide26$38,745
JanuviaSitagliptin Phosphate40$35,316
MounjaroTirzepatide31$31,191
FarxigaDapagliflozin Propanediol26$19,532
Toujeo SolostarInsulin Glargine,hum.Rec.Anlog13$18,383
EntrestoSacubitril/Valsartan14$13,346
XareltoRivaroxaban15$11,426
TradjentaLinagliptin11$10,441
VascepaIcosapent Ethyl14$8,133
Combivent RespimatIpratropium/Albuterol Sulfate13$7,825
Lantus SolostarInsulin Glargine,hum.Rec.Anlog34$7,259

Paid to pharmacies, not to this prescriber.

Companies that both paid and supply prescribed drugs

These companies both reported payments to this provider and make drugs the provider prescribed under Medicare Part D in 2024. For most specialties this overlap is expected — a cardiologist who is paid by a cardiology drugmaker also treats heart disease. It is shown so the reader can see it, not because it implies anything on its own.

CompanyPaid to this providerPart D cost of their drugs
Novo NordiskOzempic$294$132,899103 claims
Boehringer IngelheimJardiance, Tradjenta, Combivent Respimat$88$72,33877 claims
GSKTrelegy Ellipta$151$71,97584 claims
Lilly USA, LLCTrulicity, Mounjaro$72$69,93657 claims
PfizerEliquis$124$63,84579 claims
MerckJanuvia$30$35,31640 claims
AstraZenecaFarxiga, Symbicort, Brilinta$28$30,57759 claims
NovartisEntresto$47$13,34614 claims
Johnson & JohnsonXarelto$67$11,42615 claims
AbbVieSynthroid$1,032$2,01129 claims

Reading this fairly. The Part D column is what drug plans and patients paid pharmacies — this provider received none of it, and it reflects how many patients they treat and what those drugs cost. Against peers, this provider's reported payments sit in the 80th percentile of 843 family medicine providers in West Virginia.

Other family medicine in Eleanor

See the full list for West Virginia

Where these figures come from

Is this you, or does something look wrong? →